SRR5088845
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- ANGIOGENESIS+0.400
- ALLOGRAFT_REJECTION+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- KRAS_SIGNALING_UP+0.300
- PANCREAS_BETA_CELLS+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- ADIPOGENESIS+0.200
- APICAL_SURFACE+0.200
- COAGULATION+0.200
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.600
- MITOTIC_SPINDLE-0.500
- MYC_TARGETS_V2-0.500
- MYC_TARGETS_V1-0.400
- DNA_REPAIR-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
- PI3K_AKT_MTOR_SIGNALING-0.200
- PROTEIN_SECRETION-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DS-01A-11R-A056-07 | — | B | 0.889 |
| 2 | TCGA-B6-A0IN-01A-11R-A034-07 | — | D | 0.858 |
| 3 | TCGA-21-5784-01A-01R-1635-07 | — | cohortSQ1 | 0.852 |
| 4 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.849 |
| 5 | MDT-AP-1254 | Med | Medulloblastoma | 0.844 |
| 6 | BS_M4NVX721 | Ganglioglioma | — | 0.838 |
| 7 | TCGA-GM-A2DK-01A-21R-A180-07 | — | B | 0.836 |
| 8 | ERR3262564 | — | — | 0.833 |
| 9 | TCGA-67-3772-01A-01R-0946-07 | — | cohortA1 | 0.824 |
| 10 | SRR1459211 | GTEX | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |